Renata Cifkova

Bio: Renata Cifkova is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Population & Blood pressure. The author has an hindex of 68, co-authored 305 publications receiving 80868 citations. Previous affiliations of Renata Cifkova include Masaryk University & Czechoslovak Academy of Sciences.

Intima‐media Thickness of Carotid Arteries in Borderline Hypertensives

Abstract: The purpose of this study was to assess the effect of the main risk factors for cardiovascular disease on the process of subclinical atherosclerosis in originally borderline hypertensives. The relation of far wall common carotid artery intima-media thickness (IMT CCA) measured by B-mode ultrasound to smoking, body mass index (BMI), blood pressure, lipids, and angiotensin-converting enzyme (ACE) gene polymorphism was analyzed. In 48 subjects examined (mean age, 61.9 +/- 2.54 years), median IMT CCA was 0.708 mm. Statistically significant differences in BMI (26.5 vs. 29.2 kg/m2, p < 0.025) and HDL-cholesterol level (1.42 vs. 1.1 mmol/l, p < 0.025) between the first and third tertile of IMT CCA were found. No differences were observed between "controls" and "cases" in blood pressure, total cholesterol, and triacylglycerols. No significant differences in IMT CCA were found between smokers and nonsmokers and among different alleles of the ACE gene. These data reflect the importance of HDL-cholesterol and BMI on the process of atherosclerosis within an otherwise homogeneous group of patients.

Guías de práctica clínica sobre prevención de la enfermedad cardiovascular. Versión corregida 22/07/2009

Abstract: Cuarto Grupo de Trabajo Conjunto de la Sociedad Europea de Cardiología y otras Sociedades sobre Prevención de la Enfermedad Cardiovascular en la Práctica Clínica (constituido por representantes de nueve sociedades y expertos invitados) Autores/Miembros del Grupo de Trabajo: Ian Grahama (Coordinador*), Dan Atara (Oslo, Noruega), Knut Borch-Johnsenb,c (Gentofte, Dinamarca), Gudrun Boysend (Copenhague, Dinamarca), Gunilla Burelle (Uppsala, Suecia), Renata Cifkovaf (Praga, República Checa), Jean Dallongevillea (Lille, Francia), Guy De Backera (Gante, Bélgica), Shah Ebrahima (Londres, Reino Unido), Bjørn Gjelsvikg (Oslo, Noruega), Christoph Herrmann-Lingene (Marburg, Alemania), Arno Hoesg (Utrecht, Países Bajos), Steve Humphriesa (Londres, Reino Unido), Mike Knaptonh (Londres, Reino Unido), Joep Perka (Oskarshamn, Suecia), Silvia G. Prioria (Pavía, Italia), Kalevi Pyoralaa (Kuopio, Finlandia), Zeljko Reineri (Zagreb, Croacia), Luis Ruilopea (Madrid, España), Susana Sans-Menéndeza (Barcelona, España), Wilma Scholte Op Reimera (Rotterdam, Países Bajos), Peter Weissbergh (Londres, Reino Unido), David Wooda (Londres, Reino Unido), John Yarnella (Belfast, Reino Unido) y José Luis Zamoranoa (Madrid, España)

Arterial hypertension as a public health issue in the Czech Republic.

Abstract: Hypertension increases the risk of coronary heart disease, stroke, peripheral arterial disease and heart failure Five independent cross-sectional surveys for cardiovascular risk factors have been conducted in the Czech Republic (1985, 1988, 1992, 1997/98 and 2000/01), always involving a representative population sample aged 25-64 years Over a period of 15-16 years, there was a statistically significant downward trend in population mean systolic (from 1336 +/- 202 to 1288 +/- 181 mmHg; p < 0001) and diastolic (from 841 +/- 113 to 814 +/- 100 mmHg; p < 0001) blood pressure (BP) There was also a significant decrease in the prevalence of hypertension in both sexes (from 519% to 456% in men; p < 0001; from 425% to 330% in women; p < 0001) Awareness of hypertension increased in both sexes, showing higher rates for females (men from 414% to 621%; p < 0001; women from 589% to 738%; p < 0001) Hypertension control improved significantly over the period of 15/16 years (from 39% to 179%; p < 0001), consistently showing more effective control in women The significant decrease in population mean BP seems to have contributed to the decrease in total and cardiovascular mortality in the Czech Republic observed since 1985

Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de 2012)

Abstract: Autores/Membros do Grupo de Trabalho: Joep Perk (Presidente) (Suécia)*, Guy De Backer1 (Bélgica), Helmut Gohlke1 (Alemanha), Ian Graham1 (Irlanda), Zeljko Reiner2 (Croácia), W.M. Monique Verschuren1 (Países Baixos), Christian Albus3 (Alemanha), Pascale Benlian1 (França), Gudrun Boysen4 (Dinamarca), Renata Cifkova5 (República Checa), Christi Deaton1 (RU), Shah Ebrahim1 (RU), Miles Fisher6 (RU), Giuseppe Germano1 (Itália), Richard Hobbs1,7 (RU), Arno Hoes7 (Países Baixos), Sehnaz Karadeniz8 (Turquia), Alessandro Mezzani1 (Itália), Eva Prescott1 (Dinamarca), Lars Ryden1 (Suécia), Martin Scherer7 (Alemanha), Mikko Syvänne9 (Finlândia), Wilma J.M. Scholte Op Reimer1 (Países Baixos), Christiaan Vrints1 (Bélgica), David Wood1 (RU), Jose Luis Zamorano1 (Espanha), Faiez Zannad1 (França).

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Abstract: ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

Abstract: A cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus, which occur together more often than by chance alone, have become known as the metabolic syndrome. The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting glucose, and central obesity. Various diagnostic criteria have been proposed by different organizations over the past decade. Most recently, these have come from the International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute. The main difference concerns the measure for central obesity, with this being an obligatory component in the International Diabetes Federation definition, lower than in the American Heart Association/National Heart, Lung, and Blood Institute criteria, and ethnic specific. The present article represents the outcome of a meeting between several major organizations in an attempt to unify criteria. It was agreed that there should not be an obligatory component, but that waist measurement would continue to be a useful preliminary screening tool. Three abnormal findings out of 5 would qualify a person for the metabolic syndrome. A single set of cut points would be used for all components except waist circumference, for which further work is required. In the interim, national or regional cut points for waist circumference can be used.